Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development

contact@asploro.com

Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development | Abstract

Asploro Journal of Biomedical and Clinical Case Reports

ISSN: 2582-0370

Article Type: Review Article

DOI: 10.36502/2024/ASJBCCR.6380

Asp Biomed Clin Case Rep. 2024 Nov 23;7(3):294-303

Full Text HTML

Full Text PDF

Qing Hu^1*, Bing Xiang¹
¹Department of Hematology, West China Hospital, Chengdu Shangjin Nanfu Hospital of West China Hospital, Sichuan University, Chengdu, China

Corresponding Author: Bing Xiang
Address: Department of Hematology, Sichuan University West China Hospital, No. 37, Guoxue Road, Wuhou District, Chengdu, Sichuan Province, 610041 China.
Received date: 28 October 2024; Accepted date: 16 November 2024; Published date: 23 November 2024

Citation: Hu Q, Xiang B. Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development. Asp Biomed Clin Case Rep. 2024 Nov 23;7(3):294-303.

Copyright © 2024 Hu Q, Xiang B. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Multiple Myeloma, Immunotherapy, Proteasome Inhibitors, Immunomodulatory Agents, Monoclonal Antibodies, Chimeric Antigen Receptor T Cells, Immune Checkpoint Inhibitors

Abstract

Multiple myeloma (MM) is a malignant hematologic disease characterized by the neoplastic proliferation of plasma cells in the bone marrow. It exhibits high heterogeneity, a tendency for relapse, and resistance to treatment. The primary goal of first-line therapy is to achieve deep remission and durable disease control. Current conventional treatment approaches can improve patient prognosis but have significant limitations. The emergence of novel therapies, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors, marks a new era in MM treatment. However, due to the relapsed and refractory nature of MM, future applications should consider various factors and tailor treatment strategies to individual circumstances to optimize therapeutic efficacy.